Online citations, reference lists, and bibliographies.

EAU Guidelines On Non-Muscle-invasive Urothelial Carcinoma Of The Bladder: Update 2016.

M. Babjuk, A. Boehle, M. Burger, O. Čapoun, Daniel Cohen, E. Compérat, V. Hernández, E. Kaasinen, J. Palou, M. Rouprêt, B. V. van Rhijn, S. Shariat, V. Soukup, R. Sylvester, R. Zigeuner
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
CONTEXT The European Association of Urology (EAU) panel on Non-muscle-invasive Bladder Cancer (NMIBC) released an updated version of the guidelines on Non-muscle-invasive Bladder Cancer. OBJECTIVE To present the 2016 EAU guidelines on NMIBC. EVIDENCE ACQUISITION A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines published between April 1, 2014, and May 31, 2015, was performed. Databases covered by the search included Medline, Embase, and the Cochrane Libraries. Previous guidelines were updated, and levels of evidence and grades of recommendation were assigned. EVIDENCE SYNTHESIS Tumours staged as TaT1 or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection of the bladder (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis. If the initial resection is incomplete, there is no muscle in the specimen, or a high-grade or T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups is pivotal to recommending adjuvant treatment. For patients with a low-risk tumour and intermediate-risk patients at a lower risk of recurrence, one immediate instillation of chemotherapy is recommended. Patients with an intermediate-risk tumour should receive 1 yr of full-dose bacillus Calmette-Guérin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at highest risk of tumour progression, immediate radical cystectomy (RC) should be considered. RC is recommended in BCG-refractory tumours. The long version of the guidelines is available at the EAU Web site (www.uroweb.org/guidelines). CONCLUSIONS These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. PATIENT SUMMARY The European Association of Urology has released updated guidelines on Non-muscle-invasive Bladder Cancer (NMIBC). Stratification of patients into low-, intermediate-, and high-risk groups is essential for decisions about adjuvant intravesical instillations. Risk tables can be used to estimate risks of recurrence and progression. Radical cystectomy should be considered only in case of failure of instillations or in NMIBC with the highest risk of progression.
This paper references
10.1159/000353089
Second Transurethral Resection after Ta High-Grade Bladder Tumor: A 4.5-Year Period at a Single University Center
D. Lazica (2013)
10.1016/S1078-1439(02)00290-9
Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.
T. L. Griffiths (2002)
Aberdeen Technology Assessment Review (TAR) Group. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis
G Mowatt (2011)
10.1016/j.eururo.2014.09.026
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
E. Solsona (2015)
10.1007/BF02580333
Urothelial carcinoma of the prostate
R. Goebbels (1985)
10.1111/bju.12355
Prospective randomized trial of hexylaminolevulinate photodynamic‐assisted transurethral resection of bladder tumour (TURBT) plus single‐shot intravesical mitomycin C vs conventional white‐light TURBT plus mitomycin C in newly presenting non‐muscle‐invasive bladder cancer
T. O'Brien (2013)
10.1016/S0022-5347(05)67281-3
The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.
E. Solsona (2000)
Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic Please cite this article in press as: Babjuk M, et al. EAU Guidelines Update 2016
A Stenzl (2016)
10.1016/j.eururo.2014.05.033
The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
J. Oddens (2014)
10.1016/J.EURURO.2003.09.018
Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis.
A. Lopez-Beltran (2004)
10.1016/S0302-2838(02)00068-4
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies.
M. Brausi (2002)
10.1016/j.eururo.2015.02.040
Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
L. Martínez-Piñeiro (2015)
10.1016/S0022-5347(01)66226-8
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
D. Tolley (1996)
10.1016/j.eururo.2008.01.015
The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials.
R. Sylvester (2008)
10.1097/01.JU.0000125486.92260.B2
A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.
R. Sylvester (2004)
10.1016/j.urpr.2014.07.001
TaG1 Bladder Cancer: A Third of All Primary Tumors and 80% of All Recurrences Can Be Treated in the Office Using Local Anesthesia
E. F. Sabir (2014)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
L. Sobin (1987)
10.1016/j.eururo.2013.03.059
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
M. Burger (2013)
10.1016/J.UROLOGY.2007.03.033
Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection.
Matthew J. Wasco (2007)
10.1002/cncr.24914
Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer
G. di Lorenzo (2010)
10.1016/j.eururo.2009.09.024
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.
H. Fritsche (2010)
10.1016/J.JURO.2007.05.148
Management of low grade papillary bladder tumors.
H. Herr (2007)
v.1.0, estimated cancer incidence, mortality and prevalence worldwide in 2012
J Ferlay (2012)
10.6004/JNCCN.2013.0060
Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
M. Abern (2013)
10.1111/j.1464-410X.2009.08417.x
Meta‐analysis: does lidocaine gel before flexible cystoscopy provide pain relief?
D. Aaronson (2009)
10.1016/j.eururo.2012.05.008
Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.
V. Soukup (2012)
10.1016/J.UROLOGY.2005.08.064
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.
V. Lokeshwar (2005)
10.1016/j.eururo.2012.07.033
Epidemiology and risk factors of urothelial bladder cancer.
M. Burger (2013)
10.1016/S0022-5347(01)66338-9
Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications.
E. Solsona (1996)
Calmette-Gué rin, and bacillus Calmette-Gué rin plus isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder
(2010)
10.1111/j.1464-410X.2011.10904.x
The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer
Mario Richterstetter (2012)
10.1016/J.EURURO.2006.05.021
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy.
S. Shariat (2007)
10.1016/j.juro.2009.06.017
Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
O. Nativ (2009)
10.1016/S0302-2838(02)00006-4
Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis.
M. Raitanen (2002)
Histologic typing of urinary bladder tumors
F K Mostofi
10.1002/ijc.28693
Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai
R. Corral (2014)
[Practical guideline for the management of adverse events associated with BCG installations].
F. Rodríguez (2008)
10.1016/j.eururo.2012.08.057
Smoking reduces the efficacy of intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer.
Michael Rink (2012)
10.1016/j.eururo.2011.04.023
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review.
R. Lammers (2011)
10.1097/01.JU.0000173919.28835.AA
Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
J. A. Martínez-Piñeiro (2005)
10.1016/J.EURURO.2003.12.010
Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
M. Kuroda (2004)
10.1111/his.12214
An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps
E. Compérat (2013)
10.1038/modpathol.2008.193
Diagnosis of urothelial carcinoma from urine
B. Tětu (2009)
10.1016/J.EURURO.2009.05.047
Detrusor Muscle in the First, Apparently Complete Transurethral Resection of Bladder Tumour Specimen Is a Surrogate Marker of Resection Quality, Predicts Risk of Early Recurrence, and Is Dependent on Operator Experience
G. Dalbagni (2010)
10.1016/j.juro.2013.01.084
A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer.
A. Sengiku (2013)
10.1016/J.UROLONC.2005.11.026
Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.
F. Joudi (2006)
10.1159/000019859
Significance of Bladder Biopsies in Ta,T1 Bladder Tumors: A Report from the EORTC Genito-Urinary Tract Cancer Cooperative Group
A. V. D. van der Meijden (1999)
10.1016/j.juro.2013.08.022
The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
J. Sfakianos (2014)
10.1016/j.eururo.2012.10.039
Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.
J. Oddens (2013)
10.1016/S0022-5347(05)64043-8
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.
A. Boehle (2003)
10.1016/S0022-5347(05)67707-5
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
D. Lamm (2000)
10.1111/j.1464-410X.2010.09903.x
Bipolar energy for transurethral resection of bladder tumours at low‐power settings: initial experience
N. Gupta (2011)
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer
J. Ferlay (2013)
10.1016/j.urolonc.2007.06.002
UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing.
T. Hajdinjak (2008)
10.1016/S1470-2045(05)70472-1
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
S. D. Di Stasi (2006)
10.1016/J.EURSUP.2008.08.001
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy-Associated Adverse Events.
J. A. Witjes (2008)
10.1016/j.eururo.2011.11.011
Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?
S. Holmäng (2012)
10.1097/01.JU.0000149163.08521.69
A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database.
P. Mariappan (2005)
10.1016/j.juro.2014.09.109
Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin.
A. Morales (2015)
10.1093/JNCI/93.8.597
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
J. Au (2001)
10.1016/j.eururo.2015.06.045
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Samantha Cambier (2016)
10.7748/ns.6.46.8.s16
The World Health Organization.
Carmen Dolea (1962)
A multicenter prospective randomized trial
S. G. Smith (1991)
10.1016/j.eururo.2009.03.052
Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications.
M. May (2010)
10.1016/j.eururo.2015.02.022
Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised Fi
R. Järvinen (2015)
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer
M Duchek (2010)
10.32388/pfg7jq
International agency for research on cancer.
J. Higginson (1974)
10.1097/00000372-197900120-00004
Carcinoma in situ.
C. Smith (1978)
10.1016/j.eururo.2009.04.009
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
R. Järvinen (2009)
10.1016/j.eururo.2011.07.010
Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer.
R. Lammers (2011)
10.1016/j.eururo.2015.05.050
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from
R. Sylvester (2016)
10.1016/S0022-5347(05)01002-5
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
R. T. Divrik (2006)
10.1016/S0022-5347(05)67137-6
Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups.
F. Millán-Rodríguez (2000)
5 mg) versus mitomycin C
Calmette-Gué Rin (2007)
10.1097/01.JU.0000162059.64886.1C
Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
R. Sylvester (2005)
10.1016/J.JURO.2006.11.090
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
G. Raj (2007)
10.1016/j.eururo.2014.02.061
Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
C. Rentsch (2014)
10.1016/J.EURURO.2005.12.029
Watchful waiting policy in recurrent Ta G1 bladder tumors.
O. Gofrit (2006)
10.1111/j.1464-410X.2003.04655.x
Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials
M. Shelley (2004)
10.1590/S1677-55382010000400024
Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd
Andreas Bohle (2010)
10.1016/S0022-5347(05)66443-9
Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
S. Holmäng (2001)
10.1111/j.1464-410X.2008.07966.x
Quality control in transurethral resection of bladder tumours
H. Herr (2008)
10.1016/j.juro.2009.07.016
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
J. Fernández-Gómez (2009)
10.1016/J.EURURO.2005.12.031
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
R. Sylvester (2006)
Pathology and genetics of tumours of the urinary system and male genital organs
J. Eble (2004)
10.1016/J.UROLOGY.2005.12.014
Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.
R. Han (2006)
10.1016/j.eururo.2013.10.001
International variations in bladder cancer incidence and mortality.
Saurabh Chavan (2014)
10.1007/s00330-006-0386-z
Understanding multislice CT urography techniques: many roads lead to Rome
C. Nolte-Ernsting (2006)
10.1111/j.1464-410X.2009.09100.x
Pathological stage review is indicated in primary pT1 bladder cancer
B. V. van Rhijn (2010)
10.1111/j.1464-410X.2009.08543.x
A single‐institution experience with induction and maintenance intravesical docetaxel in the management of non‐muscle‐invasive bladder cancer refractory to bacille Calmette‐Guérin therapy
L. Barlow (2009)
10.1016/j.eururo.2014.08.062
Re: Paolo Gontero, Richard Sylvester, Francesca Pisano, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol 2015;67:74-82.
F. Montorsi (2015)
10.1016/S0022-5347(05)64273-5
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.
R. Sylvester (2002)
10.1016/j.juro.2009.08.083
Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
K. S. Cho (2009)
10.1111/j.1464-410X.2012.11500.x
Narrow band imaging diagnosis of bladder cancer: systematic review and meta‐analysis
Changjian Zheng (2012)
10.1016/J.UROLOGY.2005.06.135
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.
R. Sylvester (2005)
10.1371/journal.pone.0083192
Reproducibility and Prognostic Value of WHO1973 and WHO2004 Grading Systems in TaT1 Urothelial Carcinoma of the Urinary Bladder
Ok Målfrid Mangrud (2014)
10.1016/j.eururo.2009.09.038
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
Miloš Duchek (2010)
10.1002/cncr.25523
Detection and clinical outcome of urinary bladder cancer with 5‐aminolevulinic acid‐induced fluorescence cystoscopy
A. Stenzl (2011)
10.1111/j.1464-410X.1989.tb05159.x
Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
A. Giesbers (1989)
GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012
J. Ferlay (2013)
10.1590/S1677-55382009000600025
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer
Andreas Bohle (2009)
10.1016/j.eururo.2009.05.047
Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience.
P. Mariappan (2010)
10.1016/j.eururo.2009.09.037
Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy.
R. Draga (2010)
10.1016/j.eururo.2013.06.009
Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.
N. Perlis (2013)
10.1016/j.eururo.2009.10.030
Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study.
M. Schumacher (2010)
10.1097/01.JU.0000091800.15071.52
Carcinoma in a bladder diverticulum: presentation and treatment outcome.
D. Golijanin (2003)
10.1016/j.urolonc.2014.06.008
Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
F. Yafi (2015)
Significance of bladder biopsies in Ta , T 1 bladder tumors : a report from the EORTC GenitoUrinary Tract Cancer Cooperative Group . EORTC - GU Group Superficial Bladder Com
A vanderMeijden (1999)
10.1016/j.eururo.2014.06.040
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
P. Gontero (2015)
Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
M. Huncharek (2001)
10.1038/bjc.2012.112
Occupational cancer burden in Great Britain
L. Rushton (2012)
Histologic typing of urinary bladder tumors. International Histological Classification of Tumors, No. 10
FK Mostofi (1973)
Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin
R J Sylvester
10.1016/J.UROLOGY.2003.11.049
Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
A. Boehle (2004)
10.1111/j.1442-2042.2008.02241.x
Risk of concomitant carcinoma in situ determining biopsy candidates among primary non‐muscle‐invasive bladder cancer patients: Retrospective analysis of 173 Japanese cases
Tomohiko Hara (2009)
10.1016/j.eururo.2012.08.055
Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
D. Yates (2012)
10.1111/j.1464-410X.2011.10571.x
Good quality white‐light transurethral resection of bladder tumours (GQ‐WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non‐muscle‐invasive bladder cancer: validation across time and place and recommendation for benchmar
P. Mariappan (2012)
10.1016/S0022-5347(05)65468-7
Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo.
A. Boehle (2002)
10.1016/j.eururo.2011.10.029
Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
J. Palou (2012)
10.1016/j.urology.2008.12.047
Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
J. Palou (2009)
10.1016/j.juro.2011.10.032
Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria.
H. Herr (2012)
10.1046/j.1464-410x.2001.02306.x
A systematic review of intravesical bacillus Calmette‐Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
M. Shelley (2001)
10.1097/01.JU.0000169424.79702.6D
Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor.
J. Palou (2005)
10.1111/j.1464-410X.2012.10939.x
Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome
P. Turker (2012)
10.1111/j.1442-2042.2008.02012.x
Clinical outcomes of bacillus Calmette‐Guérin instillation therapy for carcinoma in situ of urinary bladder
A. Takenaka (2008)
10.1016/J.EURURO.2004.05.003
One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?
J. Oddens (2004)
10.1001/jama.2011.1142
Association between smoking and risk of bladder cancer among men and women.
N. Freedman (2011)
10.1016/J.EURURO.2007.04.062
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
A. Ojea (2007)
10.1016/j.juro.2013.12.004
Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial.
Vivek Venkatramani (2014)
10.1016/j.urolonc.2014.04.005
Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
Y. Neuzillet (2014)
10.1016/j.juro.2009.08.150
Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.
M. V. D. van der Aa (2010)
10.1097/01.coc.0000135570.37287.7f
The Influence of Intravesical Therapy on Progression of Superficial Transitional Cell Carcinoma of the Bladder: A Metaanalytic Comparison of Chemotherapy versus Bacilli Calmette-Guerin Immunotherapy
M. Huncharek (2004)
10.1097/00000478-199810000-00016
TNM Classification of Malignant Tumors
D. Carter (1998)
10.1016/S0022-5347(05)64553-3
Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care.
W. Murphy (2002)
10.5489/cuaj.1514
Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer.
M. Bishr (2014)
10.1016/J.EURURO.2005.05.021
Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder.
M. U. Mungan (2005)
10.1016/j.eururo.2009.12.024
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd
R. Sylvester (2010)
10.1017/S0266462310001364
Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis.
G. Mowatt (2011)
10.1016/S0302-2838(03)00140-4
Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study.
E. Kaasinen (2003)
10.1002/ijc.25592
Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC)
M. Ros (2011)



This paper is referenced by
10.3389/fonc.2019.01266
Urine Biopsy—Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer
Uttam Satyal (2019)
10.1136/bmjopen-2017-020500
Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study
J. Catto (2018)
10.1002/cncr.30392
Non–muscle‐invasive bladder cancer: Intravesical treatments beyond Bacille Calmette‐Guérin
Vignesh T. Packiam* (2017)
10.2967/jnumed.119.236430
PET/CT Imaging with an 18F-Labeled Galactodendritic Unit in a Galectin-1–Overexpressing Orthotopic Bladder Cancer Model
Patrícia M. R. Pereira (2020)
10.1111/cas.14155
Genomic profile of urine has high diagnostic sensitivity compared to cytology in non‐invasive urothelial bladder cancer
Y. Hirotsu (2019)
10.1097/CEJ.0000000000000525
Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme
Mitch van Hensbergen (2020)
10.1088/2515-7647/ab7bab
Advanced multimodal laser imaging tool for urothelial carcinoma diagnosis (AMPLITUDE)
S. Kurilchik (2020)
10.1016/J.PUROL.2018.07.198
La résection transurétrale de vessie de réévaluation est-elle toujours nécessaire en cas de primo-résection sous luminofluorescence par hexaminolévulinate ?
L. Doisy (2018)
10.1177/0391560319899303
How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices
Petros Sountoulides (2020)
10.1007/s00345-019-02708-8
Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis
T. Iwata (2019)
An Update on Chemohyperthermia for Non-Muscle Invasive Bladder Cancer
Conor McBride (2017)
10.1016/j.clgc.2017.12.013
Prognostic Value of Pretreatment Albumin‐to‐Globulin Ratio in Patients With Non–Muscle‐Invasive Bladder Cancer
N. Niwa (2018)
10.1007/s12253-019-00745-7
Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC)
Philipp J. Spachmann (2019)
10.4111/icu.2018.59.4.223
Can tumor recurrence be reduced with plasma-kinetic vaporization of the area around the tumor in nonmuscle invasive bladder cancer?
Yüksel Yılmaz (2018)
10.1590/0100-3984.2019.0063
Diagnostic accuracy of retrospective application of the Vesical Imaging-Reporting and Data System: preliminary results
André Martins Vaz (2020)
10.1016/j.gene.2019.02.083
miR-3622a promotes proliferation and invasion of bladder cancer cells by downregulating LASS2.
Shi Fu (2019)
10.14715/cmb/2019.65.7.2
Dietary fat intake and risk of bladder cancer: Evidence from a meta-analysis of observational studies.
Jian Wang (2019)
10.1007/s00432-018-2593-9
Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer
F. Sanguedolce (2018)
10.1186/s42047-020-00066-z
Divergent differentiation and variant morphology in invasive urothelial carcinomas – association with muscle-invasive disease
Suelen Cunha Santana (2020)
10.1007/s00432-019-03028-5
ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression
M. Papadimitriou (2019)
10.1080/14737159.2018.1469979
Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer
Marlou Maas (2018)
10.3390/cancers11121840
ANLN and TLE2 in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data
S. Wu (2019)
10.4103/UA.UA_143_18
Is cystoscopy follow-up protocol safe for low-risk bladder cancer without muscle invasion?
Ugur Yucetas (2020)
10.1186/s12943-018-0892-z
Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis
Fei Xie (2018)
10.1007/s00345-019-02853-0
Microlocalization and clinical significance of stabilin-1+ macrophages in treatment-naïve patients with urothelial carcinoma of the bladder
B. Wang (2019)
10.3233/BLC-160060
Systematic Review and Meta-Analysis on the Impact of Hexaminolevulinate- Versus White-Light Guided Transurethral Bladder Tumor Resection on Progression in Non-Muscle Invasive Bladder Cancer
G. Gakis (2016)
10.1016/j.urolonc.2018.03.015
Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial.
E. I. Liem (2018)
10.1007/s10103-020-02960-0
The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer
Sheng Xu (2020)
10.1007/s00345-018-2359-7
Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer
F. Audenet (2018)
10.3390/ijms19102999
Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer
H. Fukushima (2018)
10.1042/BSR20180214
The prognostic significance of preoperative serum albumin in urothelial carcinoma: a systematic review and meta-analysis
J. Liu (2018)
The clinical use of the BTA test for diagnosis of bladder cancer
Syryło (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar